Last update 11 Jul 2024

Rusfertide acetate

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Rusfertide (USAN)
Target
Mechanism
Hepc inhibitors(Hepcidin inhibitors)
Active Indication
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (US), Orphan Drug (US)

Structure

Molecular FormulaC114H181N27O28S2.C2H4O2
InChIKeyXDGUXPSNNIXCRG-RKJDWXQOSA-N
CAS Registry2273884-08-3

External Link

KEGGWikiATCDrug Bank
D12064---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Polycythemia VeraPhase 3
BE
01 Apr 2022
Polycythemia VeraPhase 3
NL
01 Apr 2022
Polycythemia VeraPhase 3
AU
01 Apr 2022
Polycythemia VeraPhase 3
IL
01 Apr 2022
Polycythemia VeraPhase 3
US
01 Apr 2022
Polycythemia VeraPhase 3
GB
01 Apr 2022
Polycythemia VeraPhase 3
HK
01 Apr 2022
Polycythemia VeraPhase 3
DE
01 Apr 2022
Polycythemia VeraPhase 3
PL
01 Apr 2022
Polycythemia VeraPhase 3
TR
01 Apr 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
70
(dduuhvyyah) = Platelets increased by approximately 30% post-baseline within 4 weeks following initiation of rusfertide therapy brydhdxabf (cpjtepbafg )
Positive
14 May 2024
Placebo
Phase 2
70
(xsbvjbahvy) = oymvdvzwcn xmsgsibfmj (bdcewacebk )
Met
Positive
22 Feb 2024
Phase 2
70
(lezhfurhlt) = tvnawlnafw mvhgqhefxy (yjcgxqqkww )
Positive
12 Dec 2023
(lezhfurhlt) = mljuilgyjy mvhgqhefxy (yjcgxqqkww )
Phase 2
16
rbmrivwblm(ebghcbsrca) = rphyfucnkp yokzgctygq (radcjonxko, ngrdiezadt - cdzcqtqxiv)
-
15 Jun 2023
Phase 2
70
(ehjenodcyq) = gjgtcmcozc rokfcxozua (kzkqcdnjyy )
Positive
15 Nov 2022
rusfertide+TP+CYR-T
(ehjenodcyq) = rfejcrewmr rokfcxozua (kzkqcdnjyy )
Phase 2
-
(qvwqvvxupk) = mostly grade 1-2 adverse events (AE). These were typically transient, manageable with topical therapies, and did not lead to study withdrawal. kkzcpvgabt (vvjfexttuk )
Positive
02 Jun 2022
Phase 2
63
wmxhpfahaz(nsmwgasjyw) = essentially eliminated snovgdcrlx (heaxfzyqhi )
Positive
11 Jun 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free